Hangzhou Alltest Biotech (SH:688606) Zheng Quan Ri Bao·2025-10-30 23:10Core Viewpoint - The company has announced adjustments to its 2024 restricted stock incentive plan, specifically lowering the grant price from 26.2993 yuan per share to 25.3116 yuan per share, following the implementation of a cash dividend distribution [14][20][24]. Financial Data - The financial reports for the third quarter of 2025 have not been audited, and the company has provided key financial data and indicators in RMB [3][6]. - The company reported that the net profit of the merged entity prior to the merger was 0 yuan for the current period and the previous period [6][7]. Shareholder Information - As of September 30, 2025, the company holds 973,631 shares in its repurchase account, representing 1.23% of total shares, which is not included in the top ten shareholders [4]. Investor Communication - The company will hold a performance briefing on November 10, 2025, to discuss the third-quarter results and address investor questions [9][10][11]. - Investors can submit questions from November 3 to November 7, 2025, prior to the briefing [11]. Incentive Plan Adjustments - The adjustment of the grant price is in accordance with the company's 2024 incentive plan and has been approved by the board and supervisory committee [21][22][24]. - The adjustment will not materially affect the company's financial status or operational results and is compliant with relevant laws and regulations [21][22].